Physician profile
Kee Hyon Eom
NPI 1790162402
$2,571.60
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.77 · 2020: $1,290 · 2021: $1,002 · 2022: $120 · 2023: $45.98 · 2024: $44.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $918.00 | 2020 | |
| Viiv Healthcare Company | $503.44 | 2019-2024 | Cabenuva |
| Merck Sharp & Dohme LLC | $231.35 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $206.97 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $188.24 | 2021-2023 | Vibativ |
| La Jolla Pharmaceutical Company | $131.11 | 2020-2021 | |
| Theratechnologies INC. | $104.80 | 2020-2021 | |
| Astellas Pharma US INC | $84.59 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $63.85 | 2020-2021 | |
| Melinta Therapeutics, LLC | $46.20 | 2020-2021 | |
| Abbvie INC. | $37.27 | 2021 | |
| Grt US Holding, INC. | $24.91 | 2021 | |
| Insmed, INC. | $16.24 | 2020 | |
| Shionogi INC | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kee Hyon Eom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.